S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase.

@article{Krhn2001S100BI,
  title={S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase.},
  author={Gertraud M Kr{\"a}hn and Peter Kaskel and Silvia Sander and P J Waizenh{\"o}fer and Sebastian Wortmann and Ulrike Leiter and Ralf U. Peter},
  journal={Anticancer research},
  year={2001},
  volume={21 2B},
  pages={1311-6}
}
Lactate-dehydroxynase (LDH) has been described as a leading blood parameter in patients with melanoma metastases. However, recent data indicates that levels of S100 as well as melanoma inhibiting activity (MIA) in peripheral blood, correlate with melanoma progression. The aim of this study was to evaluate tumor markers S100, MIA, LDH and albumin in peripheral blood of 373 melanoma patients. 284 patients presented with in-situ or UICC stage I/II, and 89 with stage III/IV (54 tumor-free, 29 with… CONTINUE READING